Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Insider Kevin Mcculloch Buys 25,000 Shares

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider Kevin Mcculloch acquired 25,000 shares of the stock in a transaction that occurred on Friday, June 13th. The stock was acquired at an average price of $4.38 per share, with a total value of $109,500.00. Following the completion of the transaction, the insider now directly owns 1,708,585 shares of the company’s stock, valued at $7,483,602.30. This trade represents a 1.48% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this link.

Xeris Biopharma Trading Up 1.1%

Shares of NASDAQ XERS opened at $4.40 on Tuesday. The stock has a market cap of $688.09 million, a P/E ratio of -9.78 and a beta of 0.71. Xeris Biopharma Holdings, Inc. has a 12-month low of $2.03 and a 12-month high of $6.07. The business’s fifty day simple moving average is $4.55 and its 200-day simple moving average is $4.14.

Xeris Biopharma (NASDAQ:XERS) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.01. The company had revenue of $57.80 million during the quarter, compared to analyst estimates of $57.61 million. On average, equities analysts forecast that Xeris Biopharma Holdings, Inc. will post -0.41 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have commented on the company. Piper Sandler restated a “neutral” rating and set a $4.00 price target (up from $3.00) on shares of Xeris Biopharma in a research note on Friday, March 7th. Oppenheimer upped their price target on Xeris Biopharma from $6.00 to $7.00 and gave the stock an “outperform” rating in a research note on Friday, May 9th. Wall Street Zen cut Xeris Biopharma from a “buy” rating to a “hold” rating in a research note on Thursday, May 22nd. Craig Hallum upped their price target on Xeris Biopharma from $5.00 to $6.50 and gave the stock a “buy” rating in a research note on Friday, March 7th. Finally, Leerink Partners upped their price target on Xeris Biopharma from $5.00 to $6.00 and gave the stock an “outperform” rating in a research note on Friday, March 7th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Xeris Biopharma currently has a consensus rating of “Moderate Buy” and an average price target of $6.25.

Institutional Trading of Xeris Biopharma

Several hedge funds have recently modified their holdings of XERS. Rhumbline Advisers raised its stake in shares of Xeris Biopharma by 4.3% in the fourth quarter. Rhumbline Advisers now owns 180,964 shares of the company’s stock valued at $613,000 after acquiring an additional 7,408 shares in the last quarter. Principal Financial Group Inc. increased its holdings in Xeris Biopharma by 10.5% in the fourth quarter. Principal Financial Group Inc. now owns 113,217 shares of the company’s stock valued at $384,000 after buying an additional 10,748 shares during the last quarter. Ieq Capital LLC increased its holdings in Xeris Biopharma by 24.5% in the fourth quarter. Ieq Capital LLC now owns 67,715 shares of the company’s stock valued at $230,000 after buying an additional 13,322 shares during the last quarter. Sunpointe LLC purchased a new position in Xeris Biopharma in the fourth quarter valued at $71,000. Finally, Raymond James Financial Inc. purchased a new position in Xeris Biopharma in the fourth quarter valued at $45,000. 42.75% of the stock is currently owned by institutional investors and hedge funds.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.